Drug Profile
Research programme: human papillomavirus vaccine - Genetic Immunity/DKFZ
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Deutsches Krebsforschungszentrum [DKFZ] (Germany); Genetic Immunity
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in Germany
- 12 Oct 2012 Preclinical trials in Human papillomavirus infections in Germany (unspecified route)